Altai Protocol Library

1023 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara

New Protocol: Selinexor – bortezomib – dexamethasone for previously treated myeloma

New Protocol: Selinexor – bortezomib – dexamethasone for previously treated myeloma
Study:
  • Open-label, phase 3 trial (BOSTON)
  • Multiple myeloma progressed on or after last treatment regimen, previously received 1-3 regimens
  • Selinexor – wkly bortezomib – dexamethasone (n=195) vs. twice wkly bortezomib – dexamethasone (n=207)
Efficacy:
  • ORR: 76.4% vs. 62.3% (p=0.0012)
  • Median DoR: 20.3 vs. 12.9 mos (HR: 0.81 [0.56-1.17])
  • Median PFS: 13.9 vs. 9.5 mos (HR: 0.70 [0.53-0.93])
Safety:
  • Grade 3-4 AEs: Thrombocytopenia (39% vs. 17%), neutropenia (9% vs. 3%), pneumonia (12% vs. 10%), fatigue (13% vs. 1%), nausea (8% vs. 0), diarrhea (6% vs. 1%)

Lancet 2020; 396: 1563–73

Grosicki S, et al. Once-per-week selinexor, bortezomib, and dexamethasone

versus twice-per-week bortezomib and dexamethasone in

patients with multiple myeloma (BOSTON): a randomised,

open-label, phase 3 trial.

https://doi.org/10.1016/S0140-6736(20)32292-3

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More